BCS-based Biowaiver [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2008-09-25 17:48 (6053 d 16:12 ago) – Posting: # 2408
Views: 23,587

Dear all!

BCS-based Biowaiver, IV.1.1 General aspects, page 26 (lines 985-990)
'Comparative in vitro dissolution experiments should follow current compendial standards. [...] Usual experimental conditions are e.g.: [...]No, usual compendial standards are not 500 ml, but 250 ml! We know that guidelines easily are interpreted as laws, both by regulators and the industry - what now? Follow pharmacopeias and perform the test in 250 ml (and rely on the 'e.g.' before 500 ml), or discard all established methods and develop new ones in 500 ml media?
BTW, 500 ml are in contradiction to all (?) references published on the BCS...

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
25 visitors (0 registered, 25 guests [including 2 identified bots]).
Forum time: 10:01 CEST (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5